Health ❯ Healthcare

Oncology

Cancer Treatment Breast Cancer Lung Cancer Cancer Research Clinical Trials Patient Care Cancer Treatments Pediatric Oncology Lymphoma Chemotherapy Head and Neck Cancer Multiple Myeloma Tumor Biology Drug Development Radiation Oncology Bladder Cancer Cancer Types Hematology Melanoma Precision Medicine Prostate Cancer Skin Cancer Targeted Therapy Leukemia Immunotherapy Colorectal Cancer Solid Tumors Chronic Lymphocytic Leukemia Metastatic Cancer Blood Cancers Hematologic Malignancies Targeted Therapies Tumor Types Patient Outcomes Breast Cancer Treatment Cancer Therapies Patient Support Tumors Blood Cancer Oncologists Gastric Cancer Brain Tumors Pancreatic Cancer Radiotherapy Research Studies Research Neuro-Oncology Cancer Care Gastrointestinal Cancer Acute Myeloid Leukemia Treatment Protocols Radiation Therapy Treatment Options Cancer Diagnosis Personalized Medicine Biomarkers Tumor Microenvironment Clinical Research Cancer Tumor Treatment Cervical Cancer Brain Cancer Cancer Diagnostics Treatment Strategies EGFR Mutations Cancer Biology Metastasis Urology Hematologic Cancers Cancer Prevention Cancer Detection Gynecologic Oncology Precision Oncology Brain Metastases Advanced Cancer Molecular Biology Diagnosis Treatment Outcomes Stomach Cancer Adverse Effects Survivorship Proton Therapy Oncology Societies Healthcare Infrastructure Surgical Oncology Endometrial Cancer Hepatocellular Carcinoma Tumor Markers Treatment Efficacy Drug Treatments Breast Cancer Research Medical Research Neuroendocrine Tumors Artificial Intelligence Risk Factors Types of Cancer Genetics Small Cell Lung Cancer Genetic Mutations Breast Oncology

Treating Advanced Lung Cancer Before 3 p.m. Extends Survival in Phase III Trial

Investigators urge trials to document infusion time to probe a circadian immune effect.

First Pivotal Trial Finds Cooled-Laser Prostate Therapy Effective at 3 Months With Low Morbidity

HIV Drug Maraviroc Emerges as Preclinical Candidate to Curb Glioblastoma Invasion

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Mount Sinai Deploys PRISM AI to Match Cancer Patients to Trials Systemwide

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Danielle Fishel Reports She’s ‘All Clear’ After Breast Cancer Treatment

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma